Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

Breast Cancer Research and Treatment(2021)10.1007/s10549-021-06307-3Source: DataRank Database

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer is a research paper published in Breast Cancer Research and Treatment (2021). On theSindex it has a DataRank of 1.1. It has been cited 35 times, with 29 citing works in its 1-hop citation network.

N/A

1.1DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access35 citations · 29 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02124902 NCT02547987

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 2.21)OA: greenTopics (42)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 47%Citation Network 53%

Base Score Contribution

0.538

From this paper's citation signal

Citation Network Contribution

0.596

From 25 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 29 citers.

Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer
Nature Communications202344 citations62 referencesContributes 0.061
Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis
Journal of Breast Cancer202315 citations51 referencesContributes 0.054
Identification of Pyroptosis-Related Gene Signatures and Construction of the Risk Model to Predict BCR in Prostate Cancer
Frontiers in Molecular Biosciences202213 citations52 referencesContributes 0.051
Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond
Breast Cancer Targets and Therapy202520 citations80 referencesContributes 0.038
YTHDF2 favors protumoral macrophage polarization and implies poor survival outcomes in triple negative breast cancer
iScience202423 citations87 referencesContributes 0.037

Authors (34)

Ina Chen,Jingqin Luo ORCID,Mothaffar F. Rimawi ORCID,Ian S. Hagemann ORCID,Bryan Fisk ORCID

Live enrichment

PubMed:34173924 PMC:PMC8443324 OpenAlex:https://openalex.org/W3160460588

National Cancer Institute

Grant: 1K12CA167540

National Cancer Institute

Grant: U01 CA214125-03

National Cancer Institute

Grant: K22CA188163

Cancer Prevention and Research Institute of Texas

Grant: RR140033

National Institutes of Health

Grant: R00HG007940

NCI NIH HHS

Grant: P30 CA091842

NCI NIH HHS

Grant: U01 CA214125

NCI NIH HHS

Grant: K12 CA167540

National Institutes of Health

Grant: 4R00HG007940-03

Integrated Analysis & Interpretation of Whole Genome Exome & Transcriptome Sequen

National Institutes of Health

Grant: 5U01CA214125-03

MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS

National Institutes of Health

Grant: 1K22CA188163-01

DEFINING THE REGULATORY, NON-CODING, MUTATIONAL LANDSCAPE OF BREAST CANCER

National Institutes of Health

Grant: 5K12CA167540-10

Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology

NeoImmnuneTech

FWCI

2.21

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Springer TDM

repositoryhttps://scholarworks.indianapolis.iu.edu/bitstreams/296887e1-b4ca-4fe4-9b5e-38da12791e2a/download

publisherhttps://link.springer.com/content/pdf/10.1007/s10549-021-06307-3.pdf

publisherhttps://link.springer.com/article/10.1007/s10549-021-06307-3/fulltext.html

repositoryhttps://hdl.handle.net/1805/43635

Fields of Study

Breast Cancer Treatment StudiesCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer Research03 medical and health sciences0302 clinical medicine

MeSH Terms

DocetaxelAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansNeoplasm Recurrence, LocalCarboplatinTreatment OutcomeNeoadjuvant TherapyTriple Negative Breast Neoplasms

Keywords

CarboplatinDocetaxelMedicineBreast cancerTriple-negative breast cancerOncologyInternal medicineChemotherapyGene signatureCancerImmunologyCisplatinBiologyGeneGene expressionCombination chemotherapyClinical TrialsGenomic BiomarkersImmune BiomarkersTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsHumansBreast NeoplasmsFemaleTriple Negative Breast NeoplasmsNeoplasm Recurrence, LocalNeoadjuvant Therapy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being